Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Zelnorm Approval: FDA Accepts Overseas History, Active Surveillance

Executive Summary

The approval of Novartis' Zelnorm reflects FDA's comfort with an active surveillance program proposed by the company - and the extensive post marketing safety database of the irritable bowel syndrome agent in overseas markets
Advertisement

Related Content

Novartis To Assess Zelnorm “Medguide” Distribution In Phase IV Study
Novartis Revises Zelnorm Labeling With Diarrhea, Ischemic Colitis Risk Info
Novartis Zelnorm Life-Cycle Strategy Includes PPI Fixed-Dose Combo For GERD
Novartis Zelnorm DTC Ads To Start In Fall; Resources Shifted From Field Force
FDA Objects To Novartis IBS Ads; Claims Are Zelnorm-Specific, Agency Says
Novartis Zelnorm for chronic constipation
Schering-Plough Puffs Up Asthma Line With Foradil From Novartis
Bear Stearns Healthcare Conference In Brief
Novartis Zelnorm launch
FDA Office Of Drug Safety Director-Designate Is ODE III Deputy Raczkowski
Advertisement
UsernamePublicRestriction

Register

PS040232

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel